Zika vaccine human trials: 5 things you need to know

Zika vaccine human trials: 5 things you need to know

The Center for Disease Control has finally approved two companies to perform the phase 1 of Zika vaccine human trials. Two months before the Rio Olympics begin, will this affect the outcome and lessen the chances of an outbreak happening during the Olympics?

Here are 5 things you need to know about the phase 1 of the Zika vaccine human trials.

- Advertisement -
  1. A product of two companies

Inovio Pharmaceuticals, Inc. and GeneOne Life Science, Inc. will be spearheading the clinical tests on human patients. Inovio Pharmaceuticals is an immunotherapy company which aims to fight cancer and other infectious diseases to the next level.

GeneOne Life Science, on the other hand, is an international DNA vaccine developer. Based in Seoul, South Korea, the company develops DNA vaccines to prevent and treat incurable diseases.

ALSO READ: Spain’s Pau Gasol considers freezing sperm to combat Zika Virus at Rio Olympics

2. 40 human subjects

The phase 1 clinical testing will subject 40 healthy individuals to varying dosages to identify the Zika vaccine’s effectiveness in battling Zika virus.

3. GLS-5700 is the clinical name

The Zika DNA vaccine known clinically as the GLS-5700 prevents infection from the harmful virus. The synthetic vaccine was first tested on small and large animals. It showed its effectiveness in preventing infection from the Zika virus. The vaccine will be administered through Inovio’s proprietary DNA delivery device, CELLECTRA.

ALSO READ: Zika virus won’t derail Rio Olympics

4. 58 countries affected

Though the Zika outbreak is known to affect Rio de Janeiro at large, the Zika virus was first found in Uganda. It then spread through Asia before swiftly moving across the South Pacific towards South America.

5. Results for release later this year

Inovio’s President & CEO Dr. J. Joseph Kim has projected that the results from the Zika vaccine human trials will be released later this year.

“We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year,” Dr. Kim said in a press release.

Photo courtesy:NIAID/Flickr